Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Benlong Yang"'
Publikováno v:
Precision Medical Sciences, Vol 13, Iss 2, Pp 99-106 (2024)
Abstract p95HER2 isoform is a truncated form of HER2 that retains the C terminal domain but lacks an N terminal trastuzumab binding site. From 2014 to 2016, we assessed the expression of p95HER2 expression in 59 HER2‐positive breast cancer patients
Externí odkaz:
https://doaj.org/article/7a951ce7c1964f599d6ca482e974327a
Autor:
Min He, Shuang Hao, LinXiaoxi Ma, BingQiu Xiu, BenLong Yang, ZeHao Wang, JingYan Xue, YaYun Chi, Min Xiong, JiaJian Chen, XiaoYan Huang, XiYu Liu, SongYang Wu, Qin Xiao, Yan Huang, RuoHong Shui, AYong Cao, JunJie Li, GenHong Di, WenTao Yang, Xin Hu, GuangYu Liu, KeDa Yu, YiZhou Jiang, ZhongHua Wang, ZhiMing Shao, Jiong Wu
Publikováno v:
EClinicalMedicine, Vol 74, Iss , Pp 102700- (2024)
Summary: Background: Toripalimab, a novel PD-1 antibody, is approved for treatment of multiple solid tumors; however, its neoadjuvant use with chemotherapy for triple-negative breast cancer (TNBC) remains unevaluated. Additionally, induction chemothe
Externí odkaz:
https://doaj.org/article/8620611ec0bb4bdcbdb47cc79155784e
Autor:
Jiong Wu, Zefei Jiang, Zhenzhen Liu, Benlong Yang, Hongjian Yang, Jinhai Tang, Kun Wang, Yunjiang Liu, Haibo Wang, Peifen Fu, Shuqun Zhang, Qiang Liu, Shusen Wang, Jian Huang, Chuan Wang, Shu Wang, Yongsheng Wang, Linlin Zhen, Xiaoyu Zhu, Fei Wu, Xiang Lin, Jianjun Zou
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-10 (2022)
Abstract Background Pyrotinib (an irreversible pan-ErbB inhibitor) plus capecitabine has survival benefits and acceptable tolerability in patients with HER2-positive metastatic breast cancer. We further assessed addition of pyrotinib to trastuzumab a
Externí odkaz:
https://doaj.org/article/d032fcc84aa544e0b0ed2042112d1d40
Autor:
Yuting Sang, Benlong Yang, Miao Mo, Shiyang Liu, Xujie Zhou, Jiajian Chen, Shuang Hao, Xiaoyan Huang, Guangyu Liu, Zhimin Shao, Jiong Wu
Publikováno v:
Breast, Vol 66, Iss , Pp 24-30 (2022)
Purpose: Changes in biological features and functional status make management decisions in older women with primary breast cancer complicated. We aimed to provide an overview of the clinicopathological characteristics and survival outcomes of older b
Externí odkaz:
https://doaj.org/article/03e3bc8d13be4c6fb0179e0c24fe2c91
Autor:
Shuyue Zheng, Shuang Hao, Jiajian Chen, Yingying Zhang, Benlong Yang, Xiaoyan Huang, Guangyu Liu, Zhimin Shao, Jiong Wu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe latissimus dorsi flap (LDF) is the most commonly used autologous flap for breast reconstruction (BR) in China. We conducted this study to explore the current status of BR using LDF with/without implants.MethodsThis study was a single-ce
Externí odkaz:
https://doaj.org/article/a8f2501194f04c89a674e39283076a1f
Autor:
Shuyue Zheng, Lun Li, Ming Chen, Benlong Yang, Jiajian Chen, Guangyu Liu, Zhimin Shao, Jiong Wu
Publikováno v:
Breast, Vol 63, Iss , Pp 177-186 (2022)
Purpose: Neoadjuvant therapy (NAT) is considered the standard of care for patients with HER2-positive breast cancer (BC). However, there is no proven survival benefit of NAT compared to adjuvant therapy for the survival of patients with early-stage H
Externí odkaz:
https://doaj.org/article/e6607739af1242a8b56636b90b4671bc
Autor:
Yuting Sang, Xujie Zhou, Weiru Chi, Jiajian Chen, Benlong Yang, Shuang Hao, Xiaoyan Huang, Guangyu Liu, Zhimin Shao, Jiong Wu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundNeoadjuvant chemotherapy (NAC) has evolved significantly and has been widely accepted for downstaging disease in early-stage and locally advanced breast cancer patients. Since the optimal surgical intervention for patients receiving NAC rem
Externí odkaz:
https://doaj.org/article/efc848d975994c22b16eeacff40f4ae9
Autor:
Qi Zhang, Xiaoyan Huang, Ming Chen, Lun Li, Benlong Yang, Jiong Wu, Shenglin Huang, Rong Guo, Zhi-Ming Shao, Bingqiu Xiu, Liyi Zhang, Weiru Chi, Jingyan Xue, Yayun Chi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Despite the success of HER2-targeted therapy in achieving prolonged survival in approximately 50% of treated individuals, treatment resistance is still an important challenge for HER2+ breast cancer (BC) patients. The influence of both ada
Externí odkaz:
https://doaj.org/article/a0d49a05909f4f0b9b74697a2abaa0d7
Autor:
Dechuang Jiao, Benlong Yang, Jiajian Chen, Chunjian Wang, Lidan Jin, Wenhe Zhao, Xueqiang Gao, Haibo Wang, Jun Li, Haidong Zhao, Di Wu, Zhimin Fan, Shujun Wang, Zhenzhen Liu, Yongsheng Wang, Jiong Wu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundMitoxantrone hydrochloride injection for tracing (MHI), a new strategy to identify lymph nodes, has not been tested for axillary node staging in breast cancer. This multicenter, self-controlled, non-inferiority trial aimed to evaluate MHI
Externí odkaz:
https://doaj.org/article/94114c28f33a4619b25a526700cdc507
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundCompared with older patients, young women with breast cancer (YWBCs) have a poorer prognosis and a higher risk of recurrence. Ages ≤35 years are independent risk factors for local recurrence of breast cancer. Surgery is the most important
Externí odkaz:
https://doaj.org/article/9327ea0a05e04153a9c55170af933bec